JP6530394B2 - 混入物除去方法 - Google Patents

混入物除去方法 Download PDF

Info

Publication number
JP6530394B2
JP6530394B2 JP2016532164A JP2016532164A JP6530394B2 JP 6530394 B2 JP6530394 B2 JP 6530394B2 JP 2016532164 A JP2016532164 A JP 2016532164A JP 2016532164 A JP2016532164 A JP 2016532164A JP 6530394 B2 JP6530394 B2 JP 6530394B2
Authority
JP
Japan
Prior art keywords
apo
virus
solution
range
guhcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016532164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528233A (ja
JP2016528233A5 (enExample
Inventor
ゲイリー・ウォーレン
イヴォンヌ・ブチカ
クリストフ・ケンプ
マルティン・シュトゥッキ
Original Assignee
シーエスエル、リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエスエル、リミテッド filed Critical シーエスエル、リミテッド
Publication of JP2016528233A publication Critical patent/JP2016528233A/ja
Publication of JP2016528233A5 publication Critical patent/JP2016528233A5/ja
Application granted granted Critical
Publication of JP6530394B2 publication Critical patent/JP6530394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
JP2016532164A 2013-08-08 2014-08-08 混入物除去方法 Active JP6530394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13179755.7 2013-08-08
EP13179755 2013-08-08
PCT/AU2014/000790 WO2015017888A1 (en) 2013-08-08 2014-08-08 Contaminant removal method

Publications (3)

Publication Number Publication Date
JP2016528233A JP2016528233A (ja) 2016-09-15
JP2016528233A5 JP2016528233A5 (enExample) 2017-08-31
JP6530394B2 true JP6530394B2 (ja) 2019-06-12

Family

ID=48948309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016532164A Active JP6530394B2 (ja) 2013-08-08 2014-08-08 混入物除去方法

Country Status (12)

Country Link
US (3) US10087235B2 (enExample)
EP (2) EP3030578B1 (enExample)
JP (1) JP6530394B2 (enExample)
KR (1) KR102437202B1 (enExample)
CN (2) CN109701004B (enExample)
AU (1) AU2014305646C1 (enExample)
CA (1) CA2920391C (enExample)
DK (1) DK3030578T3 (enExample)
ES (1) ES2689333T3 (enExample)
NZ (1) NZ631126A (enExample)
PL (1) PL3030578T3 (enExample)
WO (1) WO2015017888A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ631126A (en) * 2013-08-08 2018-06-29 Csl Ltd Contaminant removal method
PE20210457A1 (es) * 2018-02-19 2021-03-08 Bayer Healthcare Llc Membrana de filtro modificada y metodo
FR3090321B1 (fr) * 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
JP7576334B2 (ja) * 2019-03-29 2024-10-31 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
CN111351893A (zh) * 2020-04-28 2020-06-30 黄河三角洲京博化工研究院有限公司 一种利用离子色谱检测盐酸胍样品中胍离子含量的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
PT1534404E (pt) 2002-06-14 2007-03-30 Centocor Inc Utilização de um modificador de clatratos para promover a passagem de proteínas durante a nanofiltração
JP5600061B2 (ja) * 2007-08-17 2014-10-01 ツェーエスエル ベーリンク ゲゼルシャフト ミット ベシュレンクテル ハフツング α−１−抗トリプシンおよびアポリポタンパク質Ａ−Ｉを精製する方法
US20110178029A1 (en) * 2007-09-14 2011-07-21 Ambrx, Inc. Modified Human Apolipoprotein A-1 and Their Uses
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
WO2012000048A1 (en) * 2010-06-30 2012-01-05 Csl Limited A reconstituted high density lipoprotein formulation and production method thereof
HUE042314T2 (hu) * 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
CA3190893A1 (en) 2013-06-05 2014-12-11 Csl Limited Process for preparing apolipoprotien a-i (apo a-i)
NZ631126A (en) * 2013-08-08 2018-06-29 Csl Ltd Contaminant removal method
CN104017076B (zh) * 2014-01-06 2016-07-06 宁波博泰生物技术有限公司 载脂蛋白aⅰ抗血清的制备方法

Also Published As

Publication number Publication date
US20190119354A1 (en) 2019-04-25
EP3030578A1 (en) 2016-06-15
AU2014305646B2 (en) 2018-06-14
US11732028B2 (en) 2023-08-22
CN109701004B (zh) 2022-11-08
CA2920391A1 (en) 2015-02-12
KR20160040299A (ko) 2016-04-12
AU2014305646A1 (en) 2016-02-18
US10087235B2 (en) 2018-10-02
KR102437202B1 (ko) 2022-08-29
DK3030578T3 (en) 2018-10-15
CA2920391C (en) 2023-03-28
HK1225737B (en) 2017-09-15
AU2014305646C1 (en) 2019-01-17
EP3030578A4 (en) 2017-04-26
US10730927B2 (en) 2020-08-04
WO2015017888A8 (en) 2015-10-01
EP3030578B1 (en) 2018-07-04
CN109701004A (zh) 2019-05-03
CN105452291B (zh) 2019-03-19
US20210147509A1 (en) 2021-05-20
PL3030578T3 (pl) 2018-12-31
ES2689333T3 (es) 2018-11-13
JP2016528233A (ja) 2016-09-15
NZ631126A (en) 2018-06-29
EP3418290A1 (en) 2018-12-26
CN105452291A (zh) 2016-03-30
WO2015017888A1 (en) 2015-02-12
US20160176947A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
US11732028B2 (en) Contaminant removal method
AT514675B1 (de) Herstellung von faktor h (fh) und fh-derivaten aus plasma
JP5989641B2 (ja) リポタンパク質製剤及びその製造方法
US6921808B2 (en) Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc-globulin and a Gc-globulin medicinal product
EP2125861B1 (en) Method of purifying apolipoprotein a-1
JP5711369B2 (ja) 蛋白製剤の製造方法
CN110198952A (zh) 制备含有生物分子的高度浓缩的液体制剂的方法
RU2668831C2 (ru) Способ получения аполипопротеина a-i (аро a-i)
EP1419177B1 (en) A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine
HK40005666A (en) Contaminant removal method
HK1225737A1 (en) Contaminant removal method
EP4279066A1 (en) Ophthalmic composition including tanfanercept and exhibiting stability without use of stabilizer
RU2681413C2 (ru) Способы получения нового поколения безопасных с биологической точки зрения продуктов klh, применяемых для лечения рака, для разработки коньюгированных терапевтических вакцин и в качестве стимулирующих средств
EP3154597B1 (en) Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents
ES2547425T3 (es) Proceso para la preparación de un concentrado del FV con virus inactivados que se inicia a partir del suero humano, a un nivel de escala industrial
BR112015029902B1 (pt) Processo de obtenção de apolipoproteína a-i (apo a-i)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170724

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190516

R150 Certificate of patent or registration of utility model

Ref document number: 6530394

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250